Kymera Therapeutics (KYMR) Short-term Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Short-term Investments data on file, last reported at $506.8 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 35.81% year-over-year to $506.8 million in Q1 2026; TTM through Mar 2026 was $506.8 million, a 35.81% increase from a year earlier, with the FY2025 full-year figure at $491.3 million, up 33.32% from the prior year.
• Short-term Investments for Q1 2026 stood at $506.8 million, up from $491.3 million in the prior quarter.
• Over the last five years, Short-term Investments for KYMR reached as high as $506.8 million in Q1 2026 and fell as low as $264.9 million in Q4 2023.
• Historically, Short-term Investments has averaged $376.0 million across 5 years, with a median of $368.5 million in 2024.
• Across the five-year window, Short-term Investments jumped 58.7% in 2024 and slipped 25.48% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $338.8 million in 2022, then dropped by 21.8% to $264.9 million in 2023, then jumped by 39.1% to $368.5 million in 2024, then surged by 33.32% to $491.3 million in 2025, then advanced by 3.17% to $506.8 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $506.8 million in Q1 2026, $491.3 million in Q4 2025, and $392.7 million in Q3 2025.